Dogwood Therapeutics CMO granted 82,500 stock options

Dogwood Therapeutics, Inc. Chief Medical Officer Roger Michael Gendreau reported an equity compensation grant.

Rhea-AI Filing Summary

Dogwood Therapeutics, Inc. Chief Medical Officer Roger Michael Gendreau reported an equity compensation grant. He acquired a stock option covering 82,500 shares of Dogwood Therapeutics common stock at an exercise price of $0.00 per share.

The option was granted on March 5, 2026 and is held as a direct ownership interest. According to the disclosure, the option vests one-third on March 5, 2027, with the remaining two-thirds vesting in equal monthly installments over the following 24 months.

Insider Trade Summary

Grant/Award: 82,500 shares

Grant/Award 1 txn

Insider Gendreau Roger Michael

Role CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	82,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 82,500 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests one-third on March 5, 2027 and 1/24th monthly thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Dogwood Therapeutics (DWTX) report for Roger Michael Gendreau?

Dogwood Therapeutics reported that Chief Medical Officer Roger Michael Gendreau received a stock option grant for 82,500 shares on March 5, 2026. This is an equity compensation award, not an open-market stock purchase or sale.

How many Dogwood Therapeutics (DWTX) shares are covered by the new stock option grant?

The new stock option grant to Chief Medical Officer Roger Michael Gendreau covers 82,500 shares of Dogwood Therapeutics common stock. These options were reported as directly owned following the transaction in the Form 4 filing.

What is the exercise price of the Dogwood Therapeutics (DWTX) stock options granted to the CMO?

The stock options granted to Chief Medical Officer Roger Michael Gendreau have an exercise price of $0.00 per share. This means he does not need to pay cash to exercise the options for the underlying shares.

When do Roger Michael Gendreau’s Dogwood Therapeutics (DWTX) stock options vest?

The stock options vest over time: one-third of the grant vests on March 5, 2027, and the remaining two-thirds vest in 1/24th monthly installments thereafter, creating a multi-year vesting schedule.

Is the Dogwood Therapeutics (DWTX) stock option grant to the CMO a direct or indirect holding?

The Form 4 indicates that the 82,500-share stock option grant to Chief Medical Officer Roger Michael Gendreau is held as a direct ownership interest. No related entity or indirect ownership structure is referenced in the disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 04:17 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gendreau Roger Michael

(Last) (First) (Middle)

C/O DOGWOOD THERAPEUTICS, INC.

44 MILTON AVENUE

(Street)

ALPHARETTA GA 30009

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dogwood Therapeutics, Inc. [ DWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.86	03/05/2026		A		82,500		(1)	03/05/2036	Common Stock	82,500	$0	82,500	D

Explanation of Responses:

1. The stock option vests one-third on March 5, 2027 and 1/24th monthly thereafter.

	/s/ Greg Duncan, Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.